Altair Therapeutics Announces Commencement of a Multi-Center Phase IIa Clinical Trial of Inhaled AIR645 to Treat Asthma

SAN DIEGO--(BUSINESS WIRE)--Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.

MORE ON THIS TOPIC